Bioasis' novel approach to treatment for brain disordersFinancial Post published an article about Bioasis Technologies. The article discusses the challenges posed by the blood-brain barrier in the treatments for serious brain disorders and how Bioasis' technologies overcomes those challenges.
There was a time when big pharma couldn’t get enough of brain drugs, but the treatment of many brain disorders faced a challenge — the blood-brain barrier. The barrier evolved to protect the brain from any contagions or toxins carried by the bloodstream. However, it also isolates the brain from medications that could be beneficial in fighting neurogenerative disorders. It’s a stubborn challenge that researchers have been trying to combat. Until now, the complicated biology of the brain has defeated attempts to find a gateway into its inner workings.
Bioasis Technologies Inc. (TSXV: BTI | OTCQB: BIOAF), which is leading the way in developing ground-breaking treatments for neurogenerative disorders. The company and its technology are well-positioned for success in the current environment through the licensing of neuroscience assets. Bioasis’ approach is to deliver progranulin to the brain using its patented xB^3 platform. xB^3 is a peptide derived from an iron-binding human protein in the blood. It binds with the brain’s low-density lipoprotein receptor (LRP1), allowing it to shuttle molecules across the blood-brain barrier. By unlocking the door, xB^3 allows the entry of therapeutics into the brain.
Learn More about Bioasis Technologies: https://www.bioasis.us/
Read the full article: https://financialpost.com/business-trends/bioasis-technologies-revolutionary-approach-seeks-a-long-sought-breakthrough-in-the-treatment-of-serious-brain-disorders